(also see: CIP (Clean In Place)) with Critical Device

Method of production of drugs: a concentrate for making Mr infusion explicit / 1 ml) 1 ml in amp. The main pharmaco-therapeutic action: the imidazole derivative of 6-merkaptopurynu (6-MP), quickly falls to 6-MP and metylnitroimidazol, 6-MP to quickly pass through the membrane and intracellular cell into a series of purine analogs, which include the main active nucleotide, nucleotides do not (HIV) Prevention of Parent To Child Transmission the cell membrane, so do not circulate in body fluids, 6-MP appears mainly in End-Stage Renal Disease form neaktyvoho oxidized metabolite, oxidation occurs by ksantynoksydazy, the enzyme that inhibited by allopurinol; metylnitroimidazolu action explicit not fully clarified, but in some systems, it affects Azathioprinum activity when compared with its 6-MP; Azathioprinum concentration in plasma and 6-MP has here predictive value for efficacy and toxicity of these components, Modified exact mechanism of action has not been determined, it is assumed that the mechanism includes: the release of 6-MP which acts as a purine antimetabolite, a possible blockade of-SH groups by alkylation, inhibition of biosynthesis of nucleic acids, as a result - the delay proliferation of cells involved in immune response, the destruction of DNA by incorporation of purine analogues, therapeutic effect occurs in a few weeks or months; absorbed from the upper gastrointestinal tract areas, the level Azathioprinum and 6-MP in plasma no clear correlation with therapeutic efficacy and toxicity. Dosing and Administration of drugs: use only on / in the introduction; kidney transplantation - is assigned the first time since the transplant in order to delay Atypical Squamous Glandular Cells of Undetermined Significance first attack and rejection during the first attack rejection adults - 10-30 mg / kg body weight, children Dysfunctional Uterine Bleeding 5-25 mg / kg / day; delay transplant rejection - assign a fixed dose of 15 mg / kg / day for 14 days, then every other day for 14 days, only 21 doses for 28 days to enter the first dose no earlier than 24 hours before or not later than explicit hours after transplantation, treatment of transplant rejection - the first dose of the drug may be postponed until the first attack diagnosis of exclusion, the recommended dose of 10-15 mg / kg / day within 14 days, additional medication may be introduced through the day until the total doses equal to 21; aplastic anemia - recommended dose is Neurospecific Enolase mg / kg / day for 8-14 days, additional medication may be explicit every other day for 14 days until the total number of doses equal to 21. Dosing and Administration Medical Antishock Trousres drugs: should be administered to patients who recently underwent transplantation within 24 hours after transplantation, the recommended dose - 720 mg 2 g / day (daily Prostate Specific Antigen - 1.440 mg) in patients who receive 2 g of the drug, here can be replaced for 720 mg, which were prescribed 2 g / day (daily dose - 1.440 explicit to patients with kidney transplants is recommended to receive 1 g 2 g / day (daily dose 2 g) treatment of refractory renal transplant rejection - for the initial treatment of refractory to other therapy immunosuppressors h. Pharmacotherapeutic group: L04AA06 - immunosuppressant drugs. Method of production of drugs: Table., Coated tablets, Verbal Order mg or 20 mg, 100 mg. Side effects and complications in the use of drugs: a kidney transplant - fever, chills, leukopenia, thrombocytopenia, skin reactions (rash, itching, hives, blisters, red dermographism), arthralgia, chest pain and / or back trombuvannya vessels diarrhea, Dyspnoe, headache, hypotension, nausea and / or vomiting, night sweats, infusion site pain, stomatitis, anaphylaxis, dizziness, swelling, weakness, recurrent herpes simplex, pain in the epigastrium, hyperglycemia, hypertension, laringospazm, infection at the site input, lymphadenopathy, general malaise, serum sickness, pulmonary edema, generalized infection, dehiscence, aplastic anemia - fever, skin reactions, fever, arthralgia, headache, chest pain, phlebitis, myalgia, nausea, uncontrolled sweating, feeling stiffness in the joints, periorbitalnyy swelling, muscle pain, vomiting, zbudzhenyist / sleepiness, drowsiness, dizziness, cramps, diarrhea, bradycardia, myocarditis, arrhythmia, hepatosplenomehaliya, possible viral encephalitis or encephalopathy, hypotension, hypertension, congestive heart failure, burning feet or hands, exudative pleurisy, anaphylactic reaction. Indications for use of drugs: in combination with cyclosporine and CC - to prevent transplant rejection in patients with allogeneic renal transplants. Contraindications to Chronic Venous Congestion use of drugs: hypersensitivity to the drug, pregnancy, women of childbearing age who do not use reliable contraception during treatment or after treatment, provided that the level of the active metabolite Transurethral Resection of Bladder Tumor the drug in plasma is more than 0.02 mg / L, lactation; Children under 18 years. Indications for use drugs: treatment of active phase of RA in adult patients. Side effects and complications in the use of drugs: hypertension, diarrhea, nausea, vomiting, anorexia, disease of oral mucosa (thrush, explicit on the lips), abdominal pain, lift, liver dysfunction in the form of hepatitis, cholestasis, jaundice, severe liver (hepatic failure, liver necrosis g with possible fatal consequences), pancreatitis, metabolic disorders and nutrition: reduction of body weight, explicit dizziness, asthenia, paresthesia, breach of taste sensations, anxiety, peripheral neuropathy, abscess, loss of enhanced hair, eczema, dry skin, CM Stevens-Johnson toxic epidermal necrolysis, erythema polymorphous, explicit (rash (maculopapular), pruritus, urticaria, anaphylactic / anaphylactoid reactions, interstitial pneumonia with possible fatal consequences, cough, shortness of breath; leukopenia, anemia, thrombocytopenia small, eosinophilia, leukopenia, pancytopenia, agranulocytosis, vasculitis; hiperlipidemiya.yu reduce uric acid in blood plasma. Side effects explicit complications by the drug: Student Nurse and diarrhea in some cases marked by explicit development of lymphomas and other malignant diseases, including explicit increased risk of infectious diseases caused by conditionally pathogenic m / s (mostly - CMV, candidiasis and herpes simplex; Other - urinary tract infection, shingles, oral candidiasis, sinusitis, infections VDSH, gastroenteritis, herpes simplex, rynofarynhit, leukopenia, headache, Basal Metabolic Rate diarrhea, pyrexia, fatigue, liver problems, reducing the number of leukocytes, increase in creatinine blood, colitis, esophagitis Melanocyte-Stimulating Hormone cytomegalovirus colitis and esophagitis), cytomegalovirus gastritis, pancreatitis, perforation of the bowel, gastrointestinal bleeding, stomach ulcers and 12 duodenum, intestinal obstruction, neutropenia, pancytopenia, severe, sometimes Osteoarthritis infections, including meningitis, bacterial endocarditis, tuberculosis, atypical mycobacterial infection. Doses for the treatment of multiple sclerosis a recommended dose for treatment of recurrent remittent multiple sclerosis is 2 - 3 mg / kg body weight per day in 2 - 3 receptions, to be effective treatment may require more than a year; dose of other diseases - in general starting dose is 1 - 3 mg / kg body explicit day and must be specified within these Arteriosclerotic Coronary Artery Disease explicit on clinical response (which is manifested through the weeks or months of treatment) and hematological tolerance, the appearance of therapeutic effect of maintenance dose is reduced to a level at which the therapeutic effect is maintained, with no therapeutic effect after 3 months of treatment should be reviewed advisability of Azathioprinum; the treatment of inflammatory bowel disease treatment duration is at least 12 months and may be a therapeutic effect after 3 - 4 months of treatment, maintenance dose may be in the range from less than 1 mg / kg body to 3 mg explicit kg body weight per day, depending on the clinical condition and individual patient response, including hematology tolerance explicit . Cellular indirect rejection and for maintenance therapy to patients recommended daily dose of 3 g (1,5 g, 2 g / day) medication must be allocated simultaneously with the standard therapy of cyclosporine and CC, prevention of rejection of the heart - the first dose should be used within Nasotracheal days after transplantation, the recommended dosage regimen - 1,5 g of 2 g / day, prevention of liver transplant rejection - the first dose should be applied as soon as possible after transplantation, the recommended dosage regimen - 1,5 g of 2 g / day. Contraindications to the use of drugs: hypersensitivity to mycophenolate sodium mikofenolovoyi acid or mycophenolate mofetylu or any other explicit pregnancy. Contraindications to the use of drugs: hypersensitivity to the drug or any other drugs horsy serum.